Dianthus Reports $1.2B Cash, 75% CIDP Response Rate, and New Pipeline Asset DNTH312
DNTH has more than doubled off its 52-week low of $18.08.
Summary
Dianthus reported Q2 2026 results with $1.2B cash, a 75% CIDP response rate, and unveiled DNTH312, a new bifunctional fusion protein. Multiple pipeline catalysts are on track, with cash runway into 2030.
Key Events · Earnings and Guidance · DNTH
-
Q2 2026 Financial Results
Cash of $1.2 billion as of June 30, 2026, with runway into 2030. Net loss of $50.2 million ($0.90/share) on R&D spend of $48.7 million and G&A of $13.6 million.
-
Phase 3 CAPTIVATE CIDP Interim Data
75% response rate in Part A interim analysis (40 patients), exceeding the 50% target. Part B top-line guidance expected by year-end 2026.
-
Phase 3 EMERGE gMG Trial Initiated
Registrational trial evaluating 300mg/2mL Q2W and Q4W dosing started June 2026; top-line results anticipated in 2H'28.
-
Phase 2 MoMeNtum MMN Enrollment Complete
Enrollment exceeded target at 46 patients; top-line results on track for December 2026.
Analysis · DNTH · Life Sciences
Dianthus Therapeutics delivered a strong Q2 update: $1.2 billion in cash provides runway into 2030, well past key catalysts. The 75% response rate in the Phase 3 CAPTIVATE CIDP trial exceeded the 50% target, de-risking the program. Initiation of the Phase 3 EMERGE gMG trial and completion of enrollment in the Phase 2 MoMeNtum MMN trial with data due December 2026 add near-term milestones. The surprise announcement of DNTH312, a first-in-class bifunctional fusion protein, expands the pipeline and signals internal R&D productivity. These updates reinforce the investment thesis and justify the stock's recent strength near all-time highs.
At the time of this filing, DNTH was trading at $111.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6B. The 52-week trading range was $18.08 to $114.55. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.